NYSE:IQV - Iqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IQV stock has decreased by 14.0% and is now trading at $107.86. View which stocks have been mosted impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) issued its quarterly earnings data on Wednesday, February, 12th. The medical research company reported $1.74 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.72 by $0.02. The medical research company earned $2.90 billion during the quarter, compared to analyst estimates of $2.85 billion. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. Iqvia's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.50 EPS. View Iqvia's earnings history.

Iqvia issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided earnings per share (EPS) guidance of $7.15-7.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.22. The company issued revenue guidance of 11.775-12.000 billion, compared to the consensus revenue estimate of $11.84 billion.

17 Wall Street analysts have issued twelve-month target prices for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they expect Iqvia's share price to reach $163.56 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price. View analysts' price targets for Iqvia.

Media coverage about IQV stock has been trending positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Iqvia earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutIqvia.

Iqvia saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 2,777,500 shares, a decrease of 22.2% from the February 27th total of 3,570,000 shares. Based on an average trading volume of 1,500,000 shares, the short-interest ratio is currently 1.9 days. Currently, 1.5% of the company's shares are short sold. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PPD (PPD), PRA Health Sciences (PRAH), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), Intrexon (XON), Anavex Life Sciences (AVXL) and STARPHARMA HOLD/S (SPHRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Allergan (AGN) and Accenture (ACN).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $107.86.

Iqvia has a market capitalization of $20.75 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe. View additional information about Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]